Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

May 17, 2018 Group News

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

Amsterdam, The Netherlands – 17 May 2018

read more

Esperite’s (ESP) The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke

May 3, 2018 Group News

Esperite’s biotech company The Cell Factory, Belgium has received funding from the European Union’s Horizon 2020 research and innovation Programme for development and characterization of the extracellular vesicles (EVs) drug CF-MEV-126 for treatment of stroke. The project is focused on the development of the 2nd generation EVs drug, with enhanced anti-inflammatory and neuroprotective activities.

Amsterdam, The Netherlands – 3 May 2018

read more

Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases

March 29, 2018 Group News

Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.

Amsterdam, the Netherlands – 29 March 2018

read more

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

May 11, 2017 Group News

The Cell Factory expands its patent portfolio on extracellular vesicles biologic drugs in China.

Esperite’s (Euronext: ESP) biotech company The Cell Factory has obtained the patent for use of extracellular vesicles (EVs) in treatment of acute and chronic inflammatory and autoimmune diseases in China. This allows The Cell Factory entering into one of the largest markets of advanced therapeutics with its disruptive technology of the extracellular vesicles products replacing allogenic MSCs therapies. The Cell Factory will be presenting its EVs products: CF-MEV-107 for treatment of Crohn’s disease and CF-MEV-117 for treatment of drug resistant epilepsy during ChinaBio Partnering Forum 2017 in Zhuhai, China from May 31-June 1, 2017.

Zutphen, The Netherlands – 11 May 2017

read more

Esperite (ESP), The Cell Factory demonstrate antiinflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

May 5, 2017 Group News

CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from 18-21 May, 2017.

Zutphen, The Netherlands – 5 May 2017

read more

EN – ESPERITE financial results for 2014 published, metamorphosis completed, first positive forecast growth at €36mio Revenues (+30%) for 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.

Stem cell historical CryoSave’s core business now profitable and improving.

Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.

Zutphen, The Netherlands – 17 March 2015

read more

FR – Publication des résultats financiers 2014 de ESPERITE, métamorphose terminée, première prévision de croissance positive des revenus à 36 millions € (+30%) pour 2015

March 17, 2015 Financial Reports , Group News

ESPERITE (Esperite NV, (Euronext : ESP) « Esperite » ou « la Société ») renforce le positionnement de Genoma sur le marché par des acquisitions de technologies exclusives pour la réalisation de tests génétiques révolutionnaires entièrement certifiés.

Le coeur de métier historique de CryoSave dans les cellules souches est maintenant rentable et en constante amélioration.

Opérations consolidées, effectifs rationalisés, stratégies vente et marketing alignées, laboratoires intégrés, et processus automatisés pour l’obtention de meilleures performances et résultats.

Zutphen, Hollande – 17 Mars 2015

read more